<DOC>
	<DOCNO>NCT02360501</DOCNO>
	<brief_summary>The standard treatment strategy locally advance ( stage IVA ) metastatic ( stage IVB ) nasopharyngeal carcinoma define yet . Generally induction chemotherapy give patient order shrink tumor volume facilitate follow radiation therapy . Thus , study , investigator use combination Docetaxel+Cisplatin+Xeloda ( DCX ) treat locally advance metastatic nasopharyngeal carcinoma patient , order evaluate efficacy safety profile .</brief_summary>
	<brief_title>Combination Docetaxel , Cisplatin , Capecitabine ( DCX ) Treatment Nasopharyngeal Carcinoma</brief_title>
	<detailed_description>The standard treatment strategy locally advance ( stage IVA ) metastatic ( stage IVB ) nasopharyngeal carcinoma define yet . Generally induction chemotherapy give patient order shrink tumor volume facilitate follow radiation therapy.However , standard chemotherapy regimen define yet.Combination cisplatin fluracil commonly use regimen tolerable toxicity . Recent study find docetaxel good efficacy nasopharyngeal carcinoma patient , capecitabine safely use instead fluracil . Thus , study , use combination Docetaxel+Cisplatin+Xeloda ( DCX ) treat locally advance metastatic nasopharyngeal carcinoma patient , order evaluate efficacy safety profile .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>stage IVA IVB nasopharyngeal carcinoma lease one measurable lesion receive chemotherapy radiotherapy Eastern CooperativeOncology Group performance status 0 2 . Adequate hematologic function ( eg , white blood cell ≥ 3×10e9/l , neutrophil count ≥1.5×10e9/L , platelet count≥ 100×10e9/L ) , renal function ( eg , serum creatinine≤1.5 mg/dL creatinine clearance ≥50 mL minute ) , hepatic function ( e.g , total bilirubin≤ 2 time upper limit normal aspartate alanine transaminase level ≤ 3 time upper limit normal ) mismatch inclusion criterion previous concomitant malignancy coexist medical problem could cause poor compliance study protocol . allergy three drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>nasopharyngeal carcinoma</keyword>
	<keyword>induction chemotherapy</keyword>
	<keyword>docetaxel</keyword>
	<keyword>xeloda</keyword>
</DOC>